Evidence map›Paper›PMID 34551978›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses.

Guillaume B E Stewart-Jones, Jason Gorman, Li Ou, Baoshan Zhang, M Gordon Joyce, Lijuan Yang, Cheng Cheng, Gwo-Yu Chuang, Kathryn E Foulds, Wing-Pui Kong and 14 more

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Structure-based design of a soluble human cytomegalovirus glycoprotein B antigen stabilized in a prefusion-like conformation.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 5 institutions in 2 countries.

Guillaume B E Stewart-JonesVaccine Research Center, NIH, Bethesda, MD 20892.
Jason GormanVaccine Research Center, NIH, Bethesda, MD 20892.ORCID 0000-0002-3775-6560
Li OuVaccine Research Center, NIH, Bethesda, MD 20892.
Baoshan ZhangVaccine Research Center, NIH, Bethesda, MD 20892.
M Gordon JoyceVaccine Research Center, NIH, Bethesda, MD 20892.
Lijuan YangLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
Cheng ChengVaccine Research Center, NIH, Bethesda, MD 20892.
Gwo-Yu ChuangVaccine Research Center, NIH, Bethesda, MD 20892.
Kathryn E FouldsVaccine Research Center, NIH, Bethesda, MD 20892.
Wing-Pui KongVaccine Research Center, NIH, Bethesda, MD 20892.
Adam S OliaVaccine Research Center, NIH, Bethesda, MD 20892.ORCID 0000-0003-0805-1331
Mallika SastryVaccine Research Center, NIH, Bethesda, MD 20892.
Chen-Hsiang ShenVaccine Research Center, NIH, Bethesda, MD 20892.ORCID 0000-0002-9560-3992
John-Paul ToddVaccine Research Center, NIH, Bethesda, MD 20892.
Yaroslav TsybovskyElectron Microscopy Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
Raffaello VerardiVaccine Research Center, NIH, Bethesda, MD 20892.
Yongping YangVaccine Research Center, NIH, Bethesda, MD 20892.
Peter L CollinsLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.ORCID 0000-0001-7543-7299
Davide CortiInstitute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.ORCID 0000-0002-5797-1364
Antonio LanzavecchiaInstitute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.ORCID 0000-0002-3041-7240
Diana G ScorpioVaccine Research Center, NIH, Bethesda, MD 20892.
John R MascolaVaccine Research Center, NIH, Bethesda, MD 20892; pdkwong@nih.gov ubuchholz@niaid.nih.gov jmascola@nih.gov.
Ursula J BuchholzLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892; pdkwong@nih.gov ubuchholz@niaid.nih.gov jmascola@nih.gov.ORCID 0000-0002-2329-3198
Peter D KwongVaccine Research Center, NIH, Bethesda, MD 20892; pdkwong@nih.gov ubuchholz@niaid.nih.gov jmascola@nih.gov.ORCID 0000-0003-3560-232X
National Institute of Allergy and Infectious Diseases · USUniversità della Svizzera italiana · CHFrederick National Laboratory for Cancer Research · USHenry M. Jackson Foundation · USNew York Structural Biology Center · US

Funding

Design Of ImmunogensZIAAI005024 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2009 to 2025
$21.5M
TRD #3: An automated and streamlined pipeline for in-situ molecular microscopyP41GM103310 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI DE MARCO, ALEX, KIEFT, JEFFREY S · 2012 to 2021
$14.7M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS ZIA AI005024NCI NIH HHS HHSN261200800001ENIGMS NIH HHS P41 GM103310
6 · The paper itself

Abstract

Human metapneumovirus (HMPV) is a major cause of respiratory disease worldwide, particularly among children and the elderly. Although there is no licensed HMPV vaccine, promising candidates have been identified for related pneumoviruses based on the structure-based stabilization of the fusion (F) glycoprotein trimer, with prefusion-stabilized F glycoprotein trimers eliciting significantly higher neutralizing responses than their postfusion F counterparts. However, immunization with HMPV F trimers in either prefusion or postfusion conformations has been reported to elicit equivalent neutralization responses. Here we investigate the impact of stabilizing disulfides, especially interprotomer disulfides (IP-DSs) linking protomers of the F trimer, on the elicitation of HMPV-neutralizing responses. We designed F trimer disulfides, screened for their expression, and used electron microscopy (EM) to confirm their formation, including that of an unexpected postfusion variant. In mice, IP-DS-stabilized prefusion and postfusion HMPV F elicited significantly higher neutralizing responses than non-IP-DS-stabilized HMPV Fs. In macaques, the impact of IP-DS stabilization was more measured, although IP-DS-stabilized variants of either prefusion or postfusion HMPV F induced neutralizing responses many times the average titers observed in a healthy human cohort. Serological and absorption-based analyses of macaque responses revealed elicited HMPV-neutralizing responses to be absorbed differently by IP-DS-containing and by non-IP-DS-containing postfusion Fs, suggesting IP-DS stabilization to alter not only the immunogenicity of select epitopes but their antigenicity as well. We speculate the observed increase in immunogenicity by IP-DS trimers to be related to reduced interprotomer flexibility within the HMPV F trimer.

Indexed as

MutationAnimalsAntibodies, NeutralizingAntibodies, ViralDisulfidesEpitopesGlycoproteinsHumansImmunizationMacacaMetapneumovirusMicePromoter Regions, GeneticAntibodies, NeutralizingAntibodies, ViralDisulfidesEpitopesGlycoproteinsdisulfide-based stabilizationnonhuman primatesparamyxovirusesstructure-based vaccine designtype I fusion machines

Identifiers

PMID34551978
PMCPMC8488613
OpenAlexW3200863209

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.